智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司全资子公司浙江普洛家园药业有限公司(以下简称“家园药业”)收到欧洲药品质量管理局(以下简称 “EDQM”)签发的盐酸文拉法辛欧洲药典适用性证书(以下简称“CEP证书”)。
据悉，盐酸文拉法辛一种选择性5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI)，用于治疗各种类型抑郁症(包括伴有焦虑的抑郁症)和广泛性焦虑症。
本次公司盐酸文拉法辛原料药获得CEP证书，显示欧洲规范市场对该原料药质量的认可和肯定，标志着该产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓展国际市场带来积极影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.